Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Aquestive Therapeutics In...

    NASDAQ: AQST · Real-Time Price · USD
    3.54
    0.12 (3.51%)
    At close: Jun 16, 2025, 3:59 PM
    3.44
    -2.64%
    After-hours: Jun 16, 2025, 07:26 PM EDT
    3.51%
    Bid 3.34
    Market Cap 351.12M
    Revenue (ttm) 54.23M
    Net Income (ttm) -54.24M
    EPS (ttm) -0.58
    PE Ratio (ttm) -6.09
    Forward PE -5.61
    Analyst Buy
    Ask 3.75
    Volume 2,514,947
    Avg. Volume (20D) 1,507,301
    Open 3.58
    Previous Close 3.42
    Day's Range 3.30 - 3.61
    52-Week Range 2.12 - 5.80
    Beta 1.93

    About AQST

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol AQST
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for AQST stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    -19.65%
    Aquestive Therapeutics shares are trading lower af... Unlock content with Pro Subscription
    3 months ago
    +2.2%
    Aquestive Therapeutics shares are trading lower after the company reported worse-than-expected Q4 financial results
    news image

    1 week ago · seekingalpha.com

    Aquestive Therapeutics: Anaphylm Could Gain Significant Market Share

    Aquestive Therapeutics' Anaphylm offers a unique, non-injectable epinephrine solution for anaphylaxis, with NDA decision expected imminently. Anaphylm's advantages—wallet portability, rapid onset, and...

    news image

    1 month ago · seekingalpha.com

    Aquestive Therapeutics, Inc. (AQST) Q1 2025 Earnings Call Transcript

    Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Brian Korb - IR Dan Barber - CEO Ernie Toth - CFO Sherry Korczynski - SVP of S...

    news image

    1 month ago · zacks.com

    Aquestive Therapeutics (AQST) Reports Q1 Earnings: What Key Metrics Have to Say

    While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key me...

    news image

    1 month ago · zacks.com

    Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates

    Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.17 per share a year ago.

    news image

    1 month ago · seekingalpha.com

    Aquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside Potential

    AQST's Anaphylm, a sublingual epinephrine film, shows strong potential with FDA approval expected in Q2'25 and a $1B annual revenue target. AQST's financial health is weaker compared to competitors, w...

    news image

    2 months ago · seekingalpha.com

    Aquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells Buy

    Aquestive currently plays small ball with a handful of approved products that offer no adequate financial potential. Its recently approved Libervant, which offered greater revenue opportunity, is mire...

    Add to Watchlist